Abstract Aims Lipoprotein (a)[Lp (a)] is a causal and independent risk factor for
cardiovascular disease (CVD). People with elevated Lp (a) are often prescribed statins as …

Clinical trials of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or
statin therapy have demonstrated that baseline or treated low-density lipoprotein (LDL) …

The vascular endothelium is a dynamic endocrine organ that regulates contractile, secretory,
and mitogenic activities in the vessel wall and hemostatic processes within the vascular …

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (HRIs) have been
recently shown to prevent atherosclerosis progression. Clinical benefit results from …

Hyperlipidemia is recognized as one of the major risk factors for the development of
coronary artery disease and progression of atherosclerotic lesions. Dietary therapy together …

Abstract Background The 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase
inhibitors competitively inhibit biosynthesis of mevalonate, a precursor of non-sterol …

Background: Statins reduce cardiovascular events to a greater extent than can be explained
by their effect on lipids. Several studies have attempted to elucidate mechanisms by which …

Recent large clinical trials have demonstrated that HMG-CoA reductase inhibitors, or statins,
markedly reduce morbidity and mortality when used in the primary and secondary …

Recent clinical trials of three statins, pravastain, simvastatin and lovastatin, have
demonstrated a major reduction in acute coronary events typically precipitated by plaque …

Background and aim Studies differ with respect to the effects of statins and their on
lipoprotein (a)[Lp (a)] levels. The aim of the present study was to resolve these differences …